Serum 25(OH)D as a Biomarker for Cognitive Impairment in Parkinson Disease
Researchers sought to assess the relationship between serum 25(OH)D levels and cognition in patients with Parkinson disease.
Researchers sought to assess the relationship between serum 25(OH)D levels and cognition in patients with Parkinson disease.
Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.
This study recruited individuals aged 12-30 years who had first-degree relatives with BD I or II and those with no family history of mental illness.
Using a constructed ANN model, researchers sought to predict the long-term outcomes of microvascular decompression surgery and the factors that influence prognosis in patients with trigeminal neuralgia.
Pain of any type was a relevant factor for the sequelae of chronic inflammatory demyelinating polyneuropathy.
Researchers sought to examine whether individuals with familial hypercholesterolemia are at a heightened risk for dementia and whether statin use is tied to dementia risk.
A secondary analysis sought to identify predictors of pregabalin response in those with chronic posttraumatic neuropathic pain.
We spoke with Susan E. Schindler, MD, PhD, lead author of a study about the effect of race on the prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light.
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.